Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11368685 | 0.90 | ALDH1A1 (0.53) | DDB1CRBNALDH1A1 | |
| SCHEMBL27527936 | 0.86 | DDB1 (0.49) | OPRM1DDB1CRBNALDH1A1TACR1 | |
| SCHEMBL5213485 | 0.82 | DDB1 (0.51) | OPRM1DDB1CRBNALDH1A1HTR2C | |
| SCHEMBL16104359 | 0.82 | DDB1 (0.54) | OPRM1DDB1CRBNALDH1A1TACR1 | |
| SCHEMBL22014538 | 0.82 | OPRM1 (0.52) | OPRM1ALDH1A1 | |
| SCHEMBL6522997 | 0.81 | OPRM1 (0.56) | OPRM1HTR2CTACR1 | |
| SCHEMBL13311996 | 0.81 | DDB1 (0.56) | OPRM1DDB1CRBNALDH1A1TACR1 | |
| SCHEMBL26130614 | 0.81 | DDB1 (0.52) | OPRM1DDB1CRBNALDH1A1HTR2C | |
| SCHEMBL16875463 | 0.81 | SMN1; SMN2 (0.52) | DDB1CRBNALDH1A1 | |
| SCHEMBL16886413 | 0.81 | SMN1; SMN2 (0.52) | DDB1CRBNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| WO-2020099885-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | OPRM1 144/4885DDB1 4005/4885CRBN 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.